Advertisement

Topics

Multiple Myeloma Research Consortium Company Profile

17:56 EDT 26th September 2017 | BioPortfolio

The Multiple Myeloma Research Consortium (MMRC) is a 509(a) 3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 13 member institutions: University of California, San Francisco, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Mayo Clinic, Ohio State University, St. Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York, University Health Network (Princess Margaret Hospital), University of Chicago, University of Michigan, and Washington University.


News Articles [1543 Associated News Articles listed on BioPortfolio]

Multiple Myeloma Research Foundation to launch “Answer Fund”

The Multiple Myeloma Research Foundation (MMRF) announced that it is investing $5 million over the next three years to launch “The MMRF Answer Fund,” a multifaceted effort to address important que...

SMC approves Amgen’s carfilzomib for multiple myeloma treatment

The Scottish Medicines Consortium (SMC) has approved the routine use of Amgen’s carfilzomib (Kyprolis), in combination with dexamethasone, for the treatment of multiple myeloma across National Healt...

Front-line combinations in multiple myeloma: Highlights from EHA 2017

Professor Joy Ho (Royal Prince Alfred Hospital, Sydney, Australia) and Professor Je-Jung Lee (Chairman, Korean Multiple Myeloma Working Party) discuss current treatment paradigms in newly diagnosed mu...

Novel Quadruplet Therapy Shows Promise in Multiple Myeloma

In this interview with Charlotte Pawlyn, MB, BChir, PhD, she discusses results of the Myeloma XI study, which tested a novel quadruplet therapy for patients with newly diagnosed multiple myeloma.

Current and future prospects in treating multiple myeloma

Dr Giralt speaks with ecancer at the Best of ASCO meeting in Miami to discuss current and future prospect in treating multiple myeloma. He outlines the changing understanding of myeloma as a family o...

FDA halts two multiple myeloma Keytruda trials

Based on data from two recently halted clinical trials, the FDA is issuing this statement to inform the public, healthcare professionals and oncology clinical investigators about the risks associated ...

Multiple Myeloma Patients and Supporters Embark on Cross-Country Journey to Raise Awareness and ...

At www.RoadToVictories.com, visitors can watch inspiring stories from the cyclists, learn more about how to navigate living with multiple myeloma, and sign up for Read more...

The Binding Site Fosters Discussion of Common, but Often Missed, Symptoms of Multiple Myeloma

Yorba Linda, Ca (PRWEB) August 28, 2017 Primary care physicians see more than 50 percent of myeloma patients with early symptoms, an...

PubMed Articles [3969 Associated PubMed Articles listed on BioPortfolio]

Glomerulonephritis as a Type of Kidney Injury in Multiple Myeloma: a Report of 2 Cases.

Renal involvement in multiple myeloma has multiple etiologies. Glomerulonephritis rarely occurs in multiple myeloma and numerous case reports in the literature explain their correlation. We report 2 c...

Gene Expression Profiles in Myeloma: Ready for the Real World?

Multiple myeloma is a plasma cell malignancy characterized by molecular and clinical heterogeneity. The outcome of the disease has been dramatically improved with the advent of new drugs in the past f...

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal dam...

Targeting autophagy in multiple myeloma.

Autophagy plays an important role in plasma cell ontogeny and in the pathophysiology of multiple myeloma. Autophagy is usually considered a pro-survival mechanism, and cooperates with the ubiquitin pr...

Correlation of Th17 Cells and IL-17 Level in Multiple Myeloma Patients with Pathogenesis of Multiple Myeloma.

To explore the correlation of Th17 cell rate and IL-17 level with pathogenetis of multiple myeloma(MM).

Clinical Trials [4103 Associated Clinical Trials listed on BioPortfolio]

Nivolumab + Lenalidomide + Dexamethasone In SMM

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myelo...

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

The purpose of this research study is to determine the safety of CCI-779 and bortezomib, and the highest dose of this drug that can be given to people safely. We will also be looking at h...

Inflammatory Cytokines in Symptom Production in Multiple Myeloma

The goal of this research study is to learn about the pain and/or other symptoms that patients may experience during and after treatment for multiple myeloma (MM) and how these symptoms ma...

Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma

This research study is a Phase I/II clinical trial. It is done to determine the best doses that the investigational drug (P276-00) can be used safely. "Investigational" means that the dru...

Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma

This study involves receiving blinatumomab after high-dose melphalan and ASCT for multiple myeloma. The main purpose of this study is to: - To determine whether blinatumomab is safe and fe...

Companies [1872 Associated Companies listed on BioPortfolio]

The Multiple Myeloma Research Consortium (MMRC)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2011, mo...

The Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's dia...

Multiple Myeloma Research Foundation (MMRF)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, mo...

The Multiple Myeloma Research Foundation

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 34 percent, one of the lowest of all cancers. In 2009, ap...

The Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myelo...

More Information about "Multiple Myeloma Research Consortium" on BioPortfolio

We have published hundreds of Multiple Myeloma Research Consortium news stories on BioPortfolio along with dozens of Multiple Myeloma Research Consortium Clinical Trials and PubMed Articles about Multiple Myeloma Research Consortium for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Multiple Myeloma Research Consortium Companies in our database. You can also find out about relevant Multiple Myeloma Research Consortium Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...


Corporate Database Quicklinks



Searches Linking to this Company Record